Literature DB >> 22471709

Targeting of EPH receptor tyrosine kinases for anticancer therapy.

Eva Nievergall1, Thomas Saunders, Martin Lackmann.   

Abstract

Intense research over the past 15 years has demonstrated Eph receptors and their cell surface ephrin ligands to be one of the most prevalent and complex cell-cell communication systems; this system guides cell positioning and orchestrates tissue patterning in multicellular organisms by coordinating synchronised cell-cell adhesion or segregation of interacting cells. The expression of many Eph and ephrin family members together with their embryonic patterning functions often re-emerge during oncogenesis and have generated considerable interest as targets for anticancer therapies. The first generation of monoclonal antibodies, kinase inhibitors, and vaccines suggests considerable promise in preclinical and early clinical development, but there is little doubt that successful clinical use will rely on a comprehensive understanding of the complex and sometimes puzzling activities of Eph receptors during tumor progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22471709     DOI: 10.1615/critrevoncog.v17.i2.60

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  4 in total

Review 1.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

Review 2.  Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.

Authors:  Bénédicte Fauvel; Aziz Yasri
Journal:  MAbs       Date:  2014-05-14       Impact factor: 5.857

Review 3.  Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation.

Authors:  Dimitar B Nikolov; Kai Xu; Juha P Himanen
Journal:  Biochim Biophys Acta       Date:  2013-04-26

Review 4.  Genomics of squamous cell lung cancer.

Authors:  Melissa Rooney; Siddhartha Devarakonda; Ramaswamy Govindan
Journal:  Oncologist       Date:  2013-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.